ZM 447439

Catalog No.S1103

For research use only.

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

ZM 447439 Chemical Structure

CAS No. 331771-20-1

Selleck's ZM 447439 has been cited by 54 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Other Aurora Kinase Products

Biological Activity

Description ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
Features An Aurora selective ATP-competitive inhibitor.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
LCK [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
MEK1 [1]
(Cell-free assay)
110 nM 130 nM 880 nM 1.03 μM 1.79 μM
In vitro

In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. [1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. [2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. [3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell MmDVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjTSHpKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG4Olc5KM7:TR?= NWfvZ4ZwW0GQR1XS
MCF7 cell MnHWVJJwdGmoZYLheIlwdiCjc4PhfS=> MkDmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDNR2Y4KGOnbHygcIlv\SxiSVO1NF0xNjF7ODFOwG0> M3XMelE3OzN5MUKy
human P12-ICHIKAWA cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPMUppKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI1PDFizszN NVviOVY{W0GQR1XS
human KARPAS-45 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzyTY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6MUK4JO69VQ>? M3vYdXNCVkeHUh?=
human ES3 cell MlThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUnjeGtpUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4OzJizszN NWDNc486W0GQR1XS
human ES8 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYHCZmFyUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6QDB4IN88US=> Ml2wV2FPT0WU
human TE-11 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlO4TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVM4ODNizszN NHTwTYRUSU6JRWK=
human RS4-11 cell MnvHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4X0TWlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PTR2IN88US=> MUfTRW5ITVJ?
human MOLT-16 cell M4e5ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYxQTZzIN88US=> MXnTRW5ITVJ?
human RKO cell M1TrSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4H4NmlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NFY2PiEQvF2= NYnTUll7W0GQR1XS
human MV-4-11 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXG[GlKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd7NkOg{txO MWjTRW5ITVJ?
human SW954 cell NWm3VY9IT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64N|Y{PSEQvF2= NELweGxUSU6JRWK=
human BE-13 cell Mmf0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLQTY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFQ1OThizszN NIPK[lZUSU6JRWK=
human MOLT-4 cell NFzPcmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4O2OWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QTl5ODFOwG0> NG\HXnBUSU6JRWK=
human NBsusSR cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYDPdVFqUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MUO4O{DPxE1? M1zVV3NCVkeHUh?=
human H9 cell NVHxOohjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHWyO41KdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65Nlk4QSEQvF2= M3n1Z3NCVkeHUh?=
human A172 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4OFEyKM7:TR?= NYDyfIt3W0GQR1XS
human ES5 cell M2jSNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvLTY5pcWKrdHnvckBw\iCqdX3hckBGWzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkCwNlQ5KM7:TR?= M1zxcnNCVkeHUh?=
human SBC-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wN|kzQCEQvF2= MoXMV2FPT0WU
human NCI-H209 cell NYDYUVFmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIq0XItKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNk[wNkDPxE1? NWHJc3A3W0GQR1XS
human NKM-1 cell NFTEWmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\VXXhKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPjd7ODFOwG0> NIT2bGFUSU6JRWK=
human NCI-H720 cell NYjNZ41OT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjuRY1KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{ME[yO{DPxE1? M2j5TXNCVkeHUh?=
human KE-37 cell M4rpWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGtGNTN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yNVM5QCEQvF2= NIniTFhUSU6JRWK=
human SW48 cell NFvvUpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fCemlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlMyPTVizszN NVruN3BRW0GQR1XS
human IST-SL1 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3LTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvU1yxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{OTd{NzFOwG0> NYmyNoE6W0GQR1XS
human SK-NEP-1 cell M1Kw[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjR7ODFOwG0> M2mw[HNCVkeHUh?=
human NOMO-1 cell NW[xN2RWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLHTY5pcWKrdHnvckBw\iCqdX3hckBPV02RLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM3PzJ3IN88US=> MUjTRW5ITVJ?
human DOHH-2 cell Mo\WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWO1NZZ2UW6qaXLpeIlwdiCxZjDoeY1idiCGT1jIMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjRyMke2JO69VQ>? NV7Xe|F[W0GQR1XS
human ABC-1 cell MlPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\I[GlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQxOzV{IN88US=> Mnq5V2FPT0WU
human Ramos-2G6-4C10 cell NEO0d2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJHJidW:|LULHOk01SzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60NFYxPSEQvF2= M2OwPHNCVkeHUh?=
human EM-2 cell NXPBcpppT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkSxO|IyKM7:TR?= MWLTRW5ITVJ?
human NB14 cell M3HJ[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVPMcnRbUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PTZ{MTFOwG0> NFzjWVhUSU6JRWK=
human MOLT-13 cell M{TtfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU3PzB4IN88US=> MnHMV2FPT0WU
human ECC10 cell MoHMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfrZoxbUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjN|NUOg{txO MnrKV2FPT0WU
human LK-2 cell M33n[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHZRYFJUW6qaXLpeIlwdiCxZjDoeY1idiCOSz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PDV7NDFOwG0> NWrrRYVHW0GQR1XS
human CTB-1 cell M1Tvfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITPPFNKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PzB6MjFOwG0> NWHkSnk3W0GQR1XS
human NCI-H1581 cell NXi3dmlMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjd3NTFOwG0> NY\QUnVJW0GQR1XS
human COLO-800 cell MkG3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOECwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44ODN6MjFOwG0> M4jkd3NCVkeHUh?=
human NB7 cell NEXobGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1e0fmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63OVI6PyEQvF2= M1fSUHNCVkeHUh?=
human LAMA-84 cell NHjEdVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\nT2lvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzV3MjFOwG0> M3rKcXNCVkeHUh?=
human HCT-116 cells NXrSN3lsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2jrbWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDB7MEig{txO NHPq[2hUSU6JRWK=
SK-UT-1 cell Mm\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFf4UG9KdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjhzNUOg{txO M3e5TnNCVkeHUh?=
human H4 cell NYC0S4xlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLuVow6UW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFE2PzhizszN MWLTRW5ITVJ?
human CAL-51 cell NUnDboVYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MofRTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{QDR3IN88US=> MkLkV2FPT0WU
human LoVo cells NWDMWHpHWHKxbHnm[ZJifGmxbjDhd5NigQ>? NH3lVnY4OiCq NFnqfGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWE1j[XOnZDDXV3Q5KHKnYXflcpQh[XO|YYmsJGlEPTB;MT65JO69VQ>? MXqyOVI4ODRyMx?=
human HN cell MkXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXkcGhKdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65NlUyKM7:TR?= NUCxWGc6W0GQR1XS
human L-363 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTkUIdtUW6qaXLpeIlwdiCxZjDoeY1idiCOLUO2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTVzMjFOwG0> MWPTRW5ITVJ?
human NCI-H747 cell M3HKemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3OVnBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yM{O1N{DPxE1? M{Wwd3NCVkeHUh?=
human A498 cell M3ztPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkO2Olkh|ryP NHnac25USU6JRWK=
Assay
Methods Test Index PMID
Western blot p53 / p21 / p-p38 / p38 ; pHistone H3 / CEM ; BubR1 / MAD2 / Cyclin B1 23759594 22359551 26188358
Immunofluorescence p21 ; p53 ; Aurora B / Survivin 23759594 12719470

Protocol (from reference)

Kinase Assay:[1]
  • In vitro kinase assays :

    Recombinant Aurora A and B are expressed as NH2-terminal His6-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl2, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of 33P with a BetaplateTM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.

Cell Research:[2]
  • Cell lines: BON, QGP-1 and MIP-101 cells
  • Concentrations: 0-5 μM
  • Incubation Time: 72 hours
  • Method: Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 513.59
Formula

C29H31N5O4

CAS No. 331771-20-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ZM 447439 | ZM 447439 supplier | purchase ZM 447439 | ZM 447439 cost | ZM 447439 manufacturer | order ZM 447439 | ZM 447439 distributor